$779.53
0.53% yesterday
NYSE, Jun 30, 10:09 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$779.53
+41.86 5.67% 1M
+5.69 0.74% 6M
+7.53 0.98% YTD
-134.84 14.75% 1Y
+455.30 140.43% 3Y
+615.35 374.80% 5Y
+696.04 833.68% 10Y
+723.82 1,299.26% 20Y
NYSE, Closing price Mon, Jun 30 2025
+4.08 0.53%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Basic
Market capitalization
$738.8b
Enterprise Value
$774.1b
Net debt
$35.3b
Cash
$3.2b
Shares outstanding
947.7m
Valuation (TTM | estimate)
P/E
63.22 | 35.80
P/S
15.08 | 12.33
EV/Sales
15.80 | 12.92
EV/FCF
negative
P/B
46.86
Dividends
DPS
$5.20
Yield 1Y | 5Y
0.67% | 1.02%
Growth 1Y | 5Y
15.04% | 15.05%
Payout 1Y | 3Y
44.41% | 55.88%
Increased
10 Years
Financials (TTM | estimate)
Revenue
$49.0b | $59.9b
EBITDA
$21.6b | $26.1b
EBIT
$19.7b
Net Income
$11.1b | $20.6b
Free Cash Flow
$-1.3b
Growth (TTM | estimate)
Revenue
36.38% | 33.05%
EBITDA
66.91% | 38.65%
EBIT
73.83%
Net Income
80.93% | 94.87%
Free Cash Flow
67.41%
Margin (TTM | estimate)
Gross
81.70%
EBITDA
43.98% | 43.51%
EBIT
40.25%
Net
22.66% | 34.43%
Free Cash Flow
-2.59%
Financial Health
Equity Ratio
18.03%
Return on Equity
74.62%
ROCE
33.25%
ROIC
22.13%
Debt/Equity
2.44
More
EPS
$12.33
FCF per Share
$-1.34
Short interest
1.00%
Employees
47.00k
Rev per Employee
$960.00k
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Eli Lilly and Company forecast:

26x Buy
79%
6x Hold
18%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a Eli Lilly and Company forecast:

Buy
79%
Hold
18%
Sell
3%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
49,003 49,003
36% 36%
100%
- Direct Costs 8,969 8,969
26% 26%
18%
40,034 40,034
39% 39%
82%
- Selling and Administrative Expenses 9,110 9,110
20% 20%
19%
- Research and Development Expense 11,202 11,202
14% 14%
23%
21,551 21,551
67% 67%
44%
- Depreciation and Amortization 1,829 1,829
17% 17%
4%
EBIT (Operating Income) EBIT 19,722 19,722
74% 74%
40%
Net Profit 11,106 11,106
81% 81%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Positive
The Motley Fool
3 days ago
The market for weight management medicines has been the hottest therapeutic area in the past two years. Plenty of companies are now trying to make waves in this space.
Neutral
Invezz
5 days ago
The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity and diabetes rates collide with expanding middle-class incomes, the country is becoming a pivotal battleground for the two drugmakers.
Positive
Reuters
5 days ago
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk's recently launched Wegovy.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 47,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today